USPTO serial 76113578
Reviewed by CopyMark Law Group
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Viviana Amzel
VIVIANA AMZEL EPIGENESIS PHARMACEUTICALS, INC7 CLARKE DRCRANBURY, NJ 08512UNITED STATES| Class | Description | Status | First use |
|---|---|---|---|
| 005 | medical diagnostic and pharmaceutical preparations including steroid hormone compound(s), dehydroepiandrosterone derivatives and salts, for testing and treatment of human and non-human animal respiratory, central nervous system, immune, endocrine, neoplastic and cardiovascular ailments, including bronchoconstriction, anxiety, pre menstrual syndrome, menopause symptoms, anxiety, lack of sleep, aggressive or socially inappropriate behaviour, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, respiratory airway and pulmonary diseases and conditions, such as asthma, pulmonary vascoconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating SupraVentricular Tachycardia (SVT), adenosine stress tests, infantile Respiratory Distress Syndrome infantile ARDS, pain cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vascoconstriction, emphysema, chronic obstructive pulmonary disease (COPD) as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate | SECTION 8 - CANCELLED | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 11, 2009 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jan 18, 2008 | CFIT | CASE FILE IN TICRS | — |
| Dec 3, 2002 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 10, 2002 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 21, 2002 | NPUB | NOTICE OF PUBLICATION | — |
| Jun 7, 2002 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jan 28, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 27, 2001 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 22, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2001 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 16, 2001 | DOCK | ASSIGNED TO EXAMINER | — |